EcoDrugPlus

Protein Kinase C Epsilon

Ensembl ID : ENSXETG00000041283
Gene Symbol: PRKCE
5 View Cross-references
329 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Eta

Ensembl ID : ENSXETG00000014450
Gene Symbol: PRKCH
5 View Cross-references
237 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Gamma

Ensembl ID : ENSXETG00000010034
Gene Symbol: PRKCG
5 View Cross-references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Iota

Ensembl ID : ENSXETG00000009210
Gene Symbol: PRKCI
5 View Cross-references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Theta

Ensembl ID : ENSXETG00000018106
Gene Symbol: PRKCQ
5 View Cross-references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Theta Type

Ensembl ID : ENSXETG00000009759
Gene Symbol: LOC100498287
3 View Cross-references
26 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Theta Type

Ensembl ID : ENSXETG00000044134
Gene Symbol: LOC101734907
3 View Cross-references
26 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Theta Type

Ensembl ID : ENSXETG00000024444
Gene Symbol: LOC100488761
3 View Cross-references
26 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Theta Type

Ensembl ID : ENSXETG00000033514
Gene Symbol: LOC101735020
3 View Cross-references
26 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Theta Type-Like

Ensembl ID : ENSXETG00000022270
Gene Symbol: LOC101735024
3 View Cross-references
26 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Theta Type-Like

Ensembl ID : ENSXETG00000047014
Gene Symbol: LOC116407819
3 View Cross-references
26 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Kinase C Theta Type-Like

Ensembl ID : ENSXETG00000036379
Gene Symbol: LOC116407520
3 View Cross-references
26 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).